Cohort profile: gastric cancer in the population-based, Finnish National Esophago-Gastric Cancer Cohort (FINEGO) Study

Kauppila, Joonas H.; Ohtonen, Pasi; Rantanen, Tuomo; Tyrväinen, Tuula; Toikkanen, Vesa; Pääaho, Minna; Valtola, Antti; Räsänen, Jari; Kallio, Raija; Sihvo, Eero; Saarnio, Juha; Karttunen, Tuomo J.; Pohjanen, Vesa-Matti; Ristimäki, Ari; Laine, Seppo; Kokkola, Arto

doi:10.1136/bmjopen-2020-039574

Cited by 8 publications

(7 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cancer cohorts integrated with EHD databases show greater cost-and time-effectiveness [25][26][27]. Current findings from Scan-China reported an accuracy of linkage across baseline population and respective EHD databases.…”

Section: Strengths and Weaknessesmentioning

confidence: 93%

Integrated database-based Screening Cohort for Asian Nomadic descendants in China (Scan-China): Insights on prospective ethnicity-focused cancer screening

Yu¹,

Qiao²,

Han³

et al. 2023

Epidemiol Health

View full text Add to dashboard Cite

E p u ba h e a d o f p r i n t Declarations Data availabilityScan-China is not an open-access database. De-identification data is available on the premise of ethic approvals, once the formal email application with study proposal, statistical analysis plan, contribution statement, etc. are considered meaningful. Ethics approvalThe project was approved by the Institutional Review Board (IRB) of Ethics Committee of Inner Mongolia autonomous region Center for disease control and prevention (IRB No. NMCDCIRB2021001).Informed consent was confirmed by the IRB. The project has applied for registration in the China Clinical Trial Registration Center.

show abstract

Section: Strengths and Weaknessesmentioning

confidence: 93%

Integrated database-based Screening Cohort for Asian Nomadic descendants in China (Scan-China): Insights on prospective ethnicity-focused cancer screening

Yu¹,

Qiao²,

Han³

et al. 2023

Epidemiol Health

View full text Add to dashboard Cite

show abstract

“… 11 , 12 Patient records for patients with gastric cancer or tumor diagnosis in the Finnish Patient registry or the Finnish Cancer Registry and a relevant surgical code in the Patient Registry were retrieved from the respective health care units and hospitals and screened for eligibility by expert surgeons. 13 …”

Section: Methodsmentioning

confidence: 99%

Postoperative Complications After Neoadjuvant Chemotherapy Versus Upfront Surgery in Gastric Adenocarcinoma: A Population-Based Nationwide Study in Finland

Putila,

Helminen,

Helmiö

et al. 2023

Ann Surg Oncol

Self Cite

View full text Add to dashboard Cite

Background To date, no large population-based studies have compared complications and short-term outcomes between neoadjuvant chemotherapy and upfront surgery in gastric cancer. More nationwide studies with standardized reporting on complications are needed to enable international comparison between studies. This study aimed to compare postoperative complications between neoadjuvant therapy and upfront surgery after gastrectomy for gastric adenocarcinoma in a population-based setting. Methods This population-based study based on the Finnish National Esophago-Gastric Cancer Cohort included all patients 18 years of age or older undergoing gastrectomy for gastric adenocarcinoma in Finland during 2005–2016. Logistic regression provided odds ratios (ORs) with 95% confidence intervals (CIs), both crude and adjusted for key confounders. Different types of complications were graded based on the Esophagectomy Complications Consensus Group definitions, and major complications were assessed by the Clavien-Dindo scale. Results This study analyzed 769 patients. Neoadjuvant chemotherapy did not increase major postoperative complications after gastrectomy for gastric cancer compared with upfront surgery (OR, 1.12; 95% CI 0.81–1.56). Furthermore, it did not increase pneumonia, anastomotic complications, wound complications, or other complications. Conclusions Neoadjuvant therapy is not associated with increased postoperative complications, reoperations, or short-term mortality compared with upfront surgery in gastric adenocarcinoma.

show abstract

“…A population-based nationwide retrospective cohort study of all patients with gastric cancer in Finland during 1990–2014 was conducted 11 12…”

Section: Methodsmentioning

confidence: 99%

Gastric cancer completeness in Finnish Cancer Registry and Finnish Patient Registry: a population-based nationwide retrospective cohort study

Maharjan

Kauppila

2022

BMJ Open

Self Cite

View full text Add to dashboard Cite

BackgroundGastric cancer is the fourth-leading cause of cancer-related deaths worldwide. The only curative treatment options of gastric cancer are perioperative chemotherapy and surgical resection. Many nationwide registries have high validity and provide vast range of opportunities for registry-based research. Cancer diagnoses in the Finnish Cancer Registry (FCR) are reported by pathology laboratories and clinician forms, while discharge diagnosis codes are reported to the Finnish Patient Registry (HILMO) automatically. Finland is known for complete registries but the completeness of gastric cancer in FCR and HILMO remains unclear.ObjectivesThe aim of this study is to assess the registry coverage for gastric cancer in FCR and HILMO and to explore potential reasons for possible differences between these registries.DesignPopulation-based nationwide retrospective cohort study.ParticipantsAll patients diagnosed with gastric cancer in Finland during 1990 to 2014, with follow-up until 31 December 2019.ResultsOut of 21 468 total gastric cancers reported to either registry, 17 107 (79.7%) had a gastric cancer diagnosis in both registries. A substantial decrease from 88.3% to 83.4% was observed in the proportion of cases reported to FCR over time. The completeness of FCR was estimated at 87%. For HILMO, the completeness was 92.7%. Death due to gastric cancer was most common in those with gastric cancer in both registries (80.8%), and less common in those reported to only FCR (36.3%), followed by those reported to only HILMO (9.3%).ConclusionsThe study indicates that gastric cancer is well captured by both FCR and HILMO but there is an alarming decrease in the proportion of cases captured by the FCR over time. Some gastric cancer diagnoses in HILMO might, however, be misclassified due to cancer diagnoses being assigned based on clinical suspicion.

show abstract

Cohort profile: gastric cancer in the population-based, Finnish National Esophago-Gastric Cancer Cohort (FINEGO) Study

Cited by 8 publications

References 23 publications

Integrated database-based Screening Cohort for Asian Nomadic descendants in China (Scan-China): Insights on prospective ethnicity-focused cancer screening

Integrated database-based Screening Cohort for Asian Nomadic descendants in China (Scan-China): Insights on prospective ethnicity-focused cancer screening

Postoperative Complications After Neoadjuvant Chemotherapy Versus Upfront Surgery in Gastric Adenocarcinoma: A Population-Based Nationwide Study in Finland

Gastric cancer completeness in Finnish Cancer Registry and Finnish Patient Registry: a population-based nationwide retrospective cohort study

Contact Info

Product

Resources

About